Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
|
|
- Gabriel Marsh
- 6 years ago
- Views:
Transcription
1 601934TAR / Therapeutic Advances in Respiratory DiseaseKuk and Taylor-Cousar research-article2015 Therapeutic Advances in Respiratory Disease Review Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects Kelly Kuk and Jennifer L. Taylor-Cousar Ther Adv Respir Dis 2015, Vol. 9(6) DOI: / The Author(s), Reprints and permissions: journalspermissions.nav Abstract: Cystic fibrosis (CF) is a genetic disorder that causes multiorgan morbidity and premature death, most commonly from pulmonary dysfunction. Mutations in the CF transmembrane conductance regulator (CFTR) gene, of which almost 2000 have been described, result in a dysfunctional CFTR protein. This protein is an adenosine triphosphate binding anion channel, present primarily at the surface of epithelial cells. Loss of function mutations in this anion channel result in decreased or absent chloride/bicarbonate transport. The subsequent abnormal salt and water transport at epithelial cell surfaces leads to thickened secretions, and infection or inflammation in affected organs. In the last 20 years, therapeutics have been developed to treat the signs and symptoms of CF. However, in 2012, the small molecule drug, ivacaftor, became the first approved therapy that addresses the basic defect in CF. Ivacaftor is a potentiator of CFTR channels defective in their chloride/bicarbonate gating/conductance, but present at the epithelial cell surface. It is only approved for 10 mutations carried by approximately 7% of the population of patients with CF. F508del is the most common CFTR mutation, present in homozygosity in approximately 50% of patients with CF. The F508del mutation results in multiple CFTR channel defects that require both correction (stabilization of misfolded CFTR and trafficking to the epithelial cell membrane) and potentiation. This article reviews the in vitro and clinical trial data for the potential use of the potentiator, ivacaftor, and the corrector, lumacaftor, in patients with CF. Keywords: cystic fibrosis, cystic fibrosis transmembrane conductance regulator modulator, corrector, potentiator, ivacaftor, lumacaftor Background Cystic fibrosis Cystic fibrosis (CF) is an autosomal recessive genetic disorder that causes decreased survival with an average age of death of approximately 28 years [CFF, 2013]. CF is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene which encodes the CFTR protein, an adenosine triphosphate binding chloride anion channel that functions at the epithelial cell membrane [Ikuma and Welsh, 2000]. At this point, nearly 2000 CFTR mutations have been described [Toronto, 2015]. To varying degrees, these mutations lead to decreased salt and water transport in mucous membrane lined organs as a result of malfunctioning or absent CFTR channels [Rowe et al. 2005]. In the sinuses and lungs, this decreased salt and water transport results in thickened mucus that impairs the body s ability to clear secretions [Gibson et al. 2003]. A cycle of chronic infection and inflammation leads to tissue destruction [Gibson et al. 2003]. In the gastrointestinal tract, this abnormal mucosal surface fluid regulation leads to exocrine pancreatic dysfunction, malabsorption and intestinal obstruction [Borowitz and Gelfond, 2013]. Modulator therapy When the CFTR gene was discovered in 1989 [Kerem et al. 1989; Riordan et al. 1989; Rommens Correspondence to: Jennifer L. Taylor-Cousar, MD Departments of Internal Medicine and Pediatrics, Pulmonary Division, 1400 Jackson Street, J327, Denver, CO 80206, USA taylor-cousarj@njhealth. org Kelly Kuk, Pharm D, BCPS Department of Infectious Disease, Saint Joseph Hospital, SCL Health, Denver, CO, USA 313
2 Therapeutic Advances in Respiratory Disease 9(6) Figure 1. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR) function include potentiators and correctors. For some mutations, combination therapy will be necessary. Adapted from CFF [2015]. et al. 1989], the promise of a cure with gene therapy seemed imminent. However, available gene transport vectors proved inefficient, and clinical trials were not successful [Griesenbach and Alton, 2013]. Subsequently, CF-specific therapeutics that treat the signs and symptoms of CF lung disease were developed, including dornase alfa [Fuchs et al. 1994] (to decrease the viscosity of sputum), and inhaled tobramycin [Ramsey et al. 1999] and inhaled aztreonam [Oermann et al. 2010] (antipseudomonal antibiotics). Additional therapies that were tested in clinical trials that treat infection and inflammation [Konstan et al. 1995; Saiman et al. 2003, 2010], and improve mucus clearance [Donaldson et al. 2006; Elkins et al. 2006] have been incorporated into the daily management of this chronic disease. In combination with nutritional support, and comprehensive, coordinated care in accredited CF centers, these therapies improved the survival of patients with CF [Konstan et al. 2010; CFF, 2015]. However, it was not until recently that CFTR modulators (Figure 1), drugs that directly address the basic defect in CF, were tested and proven in clinical trials. Ivacaftor, a small molecule discovered through high throughput screening, is a CFTR potentiator (Figure 1): it increases the open probability of CFTR channels present at the epithelial cell surface that are defective in their gating, such as the G551D mutation [Van Goor et al. 2009]. Ivacaftor was tested in a phase II multidose, multicenter placebo-controlled randomized trial in 39 adults with CF [Accurso et al. 2010]. Ivacaftor was shown to improve chloride transport both by nasal potential difference measurement (NPD) and sweat chloride concentration, with a median decrease in the level of sweat chloride of 59.5 mmol/liter (range 66.0 to 19.0; p = within subject, p = 0.02 versus placebo) at 28 days. A median increase in forced expiratory volume in 1 s (FEV 1 ) of 8.7% (range ; p = for the within-subject comparison, p = 0.56 versus placebo) at day 28 was also achieved in the ivacaftor-treated subjects (Table 1). For the first time since CF was described [Andersen, 1938], these data provided proof of concept that treatment of the molecular defect was possible. Two large phase III studies were conducted in subjects with CF and at least one copy of the G551D mutation: one in subjects at least 12 years of age with FEV 1 % predicted of at least 40% and up to 90% (STRIVE) [Ramsey et al. 2011], and one in 314
3 K Kuk and JL Taylor-Cousar et al. Table 1. Summary of absolute changes compared to placebo in clinical outcomes based on modulator therapy and mutations targeted. Therapeutic agent Mutations Sweat chloride reduction FEV 1 improvement Weight or BMI improvement* Exacerbation rate reduction Ivacaftor Phase II [Accurso et al. 2010] STRIVE [Ramsey et al. 2011] ENVISION [Davies et al. 2013] KONNECTION [De Boeck et al. 2014] KONDUCT [NIH, 2015]** DISCOVER [Flume et al. 2012] Lumacaftor Phase II [Clancy et al. 2012] Lumacaftor/ ivacaftor Phase II [Boyle et al. 2014] TRAFFIC [Wainwright et al. 2015] TRANSPORT [Wainwright et al. 2015] G551D G551D G551D Non-G551D gating (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D) R117H F508del homozygotes F508del homozygotes F508del homozygotes F508del homozygotes F508del homozygotes 59.5 mmol/ liter NS NA NA 48.1mmol/ 10.5% $ 2.7 $ kg 55% $ liter $ 53.5 mmol/ 10.0% $ 2.8 $ kg NS liter $ 49.2 mmol/ liter 23.9 mmol/ liter 2.9 mmol/ liter 10.7% 0.7 kg/m 2 NA 5.0% NS NS NS NS NA 8.21 mmol/ NS NS NA liter NS 7.7% NA NA NA 2.6% NS 34% NA 3.0% 0.36 kg/m 2 43% *Through week 48. $ Reported as either weight or BMI in each study. For subjects at least 18 years of age; results NS for subjects less than 18 years of age. results provided for 200 mg dose Results provided for cohort 3 combination treatment period for 400 mg lumacaftor every 12 h plus 250 mg ivacaftor every 12 h dosing. Results provided for the 400 mg lumacaftor every 12 h plus 250 mg ivacaftor every 12 h dosing. BMI, body mass index; FEV 1, forced expiratory volume in 1 s; NA, nonapplicable (not performed); NS, nonsignificant change. ** Trial Identifier: NCT subjects at least 6 years of age with FEV 1 % predicted of at least 40% up to 105% (ENVISION) [Davies et al. 2013]. Data from these studies confirmed the results seen in the phase II study: rapid improvement in sweat chloride and lung function in the first 2 weeks of the study, as well as in weight, quality of life and rate of exacerbations that were sustained over the 24 weeks of the study (Table 1). The open-label roll-over study (PERSIST) [McKone et al. 2014] showed that results from 315
4 Therapeutic Advances in Respiratory Disease 9(6) STRIVE and ENVISON were sustained over 96 weeks. Based on the data from the phase III studies, ivacaftor was approved in 2012 for patients with the G551D mutation. This approval marked ivacaftor as the first drug in the history of CF therapeutics to be approved for treatment of the molecular defect in CF. Utilizing data from expanded access programs, ivacaftor was subsequently shown to be beneficial and well tolerated, even in those with advanced disease [Hebestreit et al. 2013; Barry et al. 2014; Taylor-Cousar et al. 2015]. Furthermore, GOAL investigators prospectively collected data on patients who were eligible to receive ivacaftor following US Food and Drug Administration (FDA) approval. In their longitudinal cohort study, the GOAL investigators showed that significant improvements in lung function, weight, and hospitalizations were achievable in patients with the G551D mutation who take ivacaftor even outside of the research setting [Rowe et al. 2014]. The G551D mutation is the most common gating defect (occurring in approximately 4% of the CF population), but there are other, more rare mutations (occurring at a combined rate of approximately 1%) that are also categorized in this class [Boyle and De Boeck, 2013]. In vitro data suggested that ivacaftor could also be efficacious for patients with other gating mutations [Yu et al. 2012]. Ivacaftor was tested in an international multicenter two-part clinical trial (KONNECTION) for patients with one of eight other gating defects (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D) [De Boeck et al. 2014]. Subjects were initially randomized in a blinded fashion to one of two sequences (beginning with ivacaftor or placebo) for 8 weeks, followed by a 4 8-week washout period prior to crossing over to the opposite sequence. All subjects were then given open-label ivacaftor in a 16-week extension period. Subjects experienced a 7.5% improvement in absolute change in FEV 1 % predicted (p < ) at 8 weeks, as well as in sweat chloride, body mass index (BMI), and quality of life. These results were sustained over the course of the extension period. Finally, based on in vitro work suggesting potential response of the conductance defect causing ( residual function ), mutation R117H [Van Goor et al. 2012], an additional phase III randomized, double-blinded 24-week clinical trial [ClinicalTrials. gov identifier: NCT ] using ivacaftor was conducted in children and adults with at least one copy of the R117H mutation. Sixty-nine patients were randomized. Although the study did not meet its primary endpoint (absolute change from baseline in FEV 1 % predicted) in the group as a whole, prespecified subgroup analysis in those subjects at least 18 years of age (n = 46) showed an absolute mean improvement in FEV 1 % predicted of 5.0 (p = 0.01). Statistically significant improvements were seen in secondary endpoints, including sweat chloride and patient-reported respiratory symptoms. Based on these results, ivacaftor was approved for use in December 2014 in patients with CF who are at least 6 years of age with the R117H mutation. Ivacaftor is clearly efficacious in patients with CF who have gating mutations or the conducting mutation R117H; however, this indication affects only 6.8% of the US CF population [CFF, 2013]. Approximately 90% of patients with CF are heterozygous for the F508del mutation and nearly 50% are homozygous for this mutation [CFF, 2013]. Compared with patients who were homozygous for the F508del mutation, those who were heterozygous for the mutation and those without the F508del mutation had lower adjusted risk for death [14%, 95% confidence interval (CI) 7 20%; and 25%, 95% CI 15 34%, respectively] [Mackenzie et al. 2014]. Unlike gating or conductance mutations, the F508del mutation causes protein misfolding that results in degradation in the endoplasmic reticulum [Thomas et al. 1992]. Thus, only a small amount of CFTR protein is trafficked to the cell surface [Denning et al. 1992]. Additionally, once at the cell surface, the small amount of F508del CFTR that is present demonstrates defective gating and increased turnover. In vitro work in F508del homozygous human bronchial epithelial human epithelial cells (HBEC) showed that ivacaftor improved CFTR-mediated chloride secretion to approximately 10% of non-cf HBEC (compared with an increase in F508del/G551D HBEC from 5% to approximately 50% of that observed in non-cf HBEC) [Van Goor et al. 2009]. At that time it was unclear how closely in vitro response would correlate with clinical response. Thus, ivacaftor monotherapy was attempted in a 16-week multicenter, randomized, double-blind, placebo-controlled trial (DISCOVER) of 140 patients homozygous for the F508del mutation [Flume et al. 2012]. As expected, based on the multiple defects that must be corrected to render the F508del protein functional (folding, processing, conductance), the randomized controlled trial of ivacaftor monotherapy did not show improvements in lung function or 316
5 K Kuk and JL Taylor-Cousar et al. other clinical endpoints (although there was a clinically insignificant but statistically significant improvement of 2.9 mmol/liter in sweat chloride; 95% CI 5.6 to 0.2, p = ). Based on these results, use of ivacaftor monotherapy in patients with CF who are homozygous for the F508del mutation is specifically excluded in the ivacaftor package insert [Vertex Pharmaceuticals, 2015]. Solely using the CFTR potentiator, ivacaftor, was insufficient to treat patients homozygous for the F508del mutation. However, data in HBEC looked promising using a CFTR corrector [Van Goor et al. 2011], a drug that improves processing and trafficking of defective CFTR to the epithelial cell surface (Figure 1). Following high throughput screening of 164,000 small molecules for their ability to improve the amount of functional F508del CFTR at the cell surface, Van Goor and colleagues tested the most efficacious compound, VX-809, in cultured HBEC from patients with CF homozygous for the F508del mutation [Van Goor et al. 2011]. They demonstrated that lumacaftor (VX-809) increased processing of F508del CFTR such that an increased amount of F508del CFTR was able to leave the Endoplasmic reticulum (ER) and be trafficked to the cell surface; chloride secretion was improved to approximately 14% of that of non-cf HBEC. Subsequently, these investigators treated the HBEC with both lumacaftor and ivacaftor. The combination increased F508del CFTR chloride secretion to approximately 25% of that of non-cf HBEC. These results suggested that using the corrector to improve processing and trafficking of F508del CFTR to the cell surface, in combination with the potentiator to increase the conductance of F508del CFTR at the cell surface, would potentially lead to a therapy that could affect at least 50% of the CF population. Pharmacokinetics While the combination of lumacaftor and ivacaftor in vitro leads to increased F508del CFTR chloride secretion acutely, subsequent in vitro studies showed that prolonged (24 48 h) administration of the two drugs resulted in a drug interaction that reduced the efficacy of lumacaftor. Specifically, in HBEC homozygous for the F508del CFTR mutation, coadministration of ivacaftor with lumacaftor led to decreased folding efficiency and stability of F508del CFTR, resulting in an increased turnover rate and reduction in mature CFTR at the cell surface [Veit et al. 2014; Cholon et al. 2014]. Cohort 1 in the phase II trial was designed to assess the potential pharmacokinetic (PK) interactions between the two drugs in order to aid with dosing parameters, and cohorts 2 3 were conducted to determine whether higher doses and longer duration of treatment might provide clinical benefit that would support phase III trials in spite of the drug drug interaction [Boyle et al. 2014]. PK findings from the study were submitted to the FDA and were reported by the FDA Clinical Pharmacology Reviewer during the Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting [FDA, 2015]. Results from the comprehensive clinical pharmacology program included the PK and metabolism of the individual drug components lumacaftor and ivacaftor as well as the combination products. Steady-state plasma concentrations of the combination of lumacaftor and ivacaftor following twice daily dosing were typically reached after approximately 7 days of treatment [FDA, 2015]. The lumacaftor accumulation ratio was approximately 1.9, whereas that of ivacaftor was lower at day 1 due to the cytochrome P450 3A (CYP3A) induction effect of lumacaftor. Drug absorption of the combination product was also affected by the intake of fatty foods with lumacaftor exposure being approximately two times higher and ivacaftor exposure being three times higher when compared with a fasting state. Both lumacaftor and ivacaftor are 99% bound to plasma proteins. Lumacaftor is not extensively metabolized so that most of the drug is excreted unchanged in the feces. It is a strong inducer of CYP3A enzymes and has a terminal half life of approximately 26 h. In contrast to lumacaftor, ivacaftor is primarily metabolized by CYP3A enzymes and excreted in the feces with a terminal half life of approximately 12 h. Considering that lumacaftor is a strong inducer of CYP3A, and ivacaftor is a CYP3A substrate, when dosed together ivacaftor exposure is reduced by lumacaftor in a dose-dependent manner. Lumacaftor exposure is not affected by ivacaftor. Findings of this clinically relevant drug drug interaction were noted in the phase II PK analysis that found when lumacaftor 400 mg every 12 h was administered with ivacaftor 150 mg twice daily, exposure is reduced by more than 80% [Clancy et al. 2012; FDA, 2015]. In vitro studies have also suggested that lumacaftor has the potential to induce CYP2B6, CYP2C8, 317
6 Therapeutic Advances in Respiratory Disease 9(6) Figure 2. Based on phase III data, absolute improvement in FEV 1 % predicted in patients receiving ivacaftor (blue bars) or lumacaftor ivacaftor combination (rust bar) with one or more of the following CFTR mutations: G551D [Ramsey et al. 2011], non-g551d gating mutation [De Boeck et al. 2014], R117H [NIH, 2015] (Trial Identifier for NIH 2015: NCT ) or F508del homozygotes [Wainwright et al. 2015]. #Subjects at least 18 years of age; *pooled data from TRAFFIC and TRAFFIC for subjects receiving lumacaftor 400 mg every 12 h and ivacaftor [Wainwright et al. 2015]. CFTR, cystic fibrosis transmembrane conductance regulator; FEV 1, forced expiratory volume in 1 s. CYP2C9, and CYP2C19 as well as inhibit CYP2C8 and CYP2C9 [FDA, 2015]. Because of the induction/substrate effects of the combination of lumacaftor and ivacaftor, the metabolism of other drugs that are metabolized by these enzymes may be altered. Therefore, many medications utilized in the management of patients with CF such as oral and intravenous antibiotics, antifungals, proton pump inhibitors, and antidepressants will require dose adjustment if used when a patient is on combination therapy [FDA, 2015]. Current evidence Phase IIa trial Based on the promising in vitro evidence of improvement of the function of F508del CFTR following combination treatment of F508del HBEC, investigators designed a phase IIa multicenter, randomized, placebo-controlled trial in adult patients with CF who were homozygous for the F508del mutation to evaluate the safety, tolerability, and PK of lumacaftor (VX-809) [Clancy et al. 2012]. Secondary outcome measures aimed at evaluation of the effect of lumacaftor on CFTR function included sweat chloride and NPD. Lung function and quality of life were also measured as secondary outcomes. Subjects were enrolled into two cohorts. In cohort A, 15 subjects were randomized in a 2:2:1 ratio to receive lumacaftor at 25 mg or 50 mg, or placebo for 28 days. Following safety review of data from the first 15 subjects by an independent data monitoring committee, 74 subjects were randomized in a 2:2:1 ratio to receive lumacaftor at a dose of 100 mg or 200 mg, or placebo for 28 days. Treatment with lumacaftor led to a dose-dependent decrease in sweat chloride values (p = ) that occurred within 7 days of drug dosing, and was sustained over the course of the trial. The mean change from baseline in sweat chloride in the highest dose (200 mg) group was 6.6 mmol/ liter (95% CI to 2.83, p = ) at 7 days, and 8.21 mmol/liter (95% CI to 2.10) at 28 days. This difference was statistically different versus placebo (p < 0.01). Sweat chloride levels returned approximately to baseline levels following a 7-day drug washout period. Although improvements were seen in sweat chloride levels, there were no differences in CFTRdependent NPD measurement in any of the dose groups. In addition, there were no changes in relative amounts of mature versus immature forms of F508del CFTR in the subgroup of patients (n = 34) who underwent rectal biopsy. Finally, there were no differences in lung function or quality of life in any of the dose groups, although the study was not powered to detect such differences
7 K Kuk and JL Taylor-Cousar et al. Generally, treatment with lumacaftor (VX-809) was safe and well tolerated. The most commonly reported adverse events in lumacaftor- and placebo-treated subjects were cough, headache, and dyspnea. Cough and dyspnea occurred in placeboversus lumacaftor-treated subjects at rates of 41% and 5.9%, and 46% and 19%, respectively. No subjects in the placebo group withdrew from the study, although one subject in each of the lumacaftor dose groups withdrew from the study. The rate of adverse respiratory events was similar between the different dose groups. Finally, there was no statistically significant difference between rate of exacerbations between the placebo-treated and lumacaftortreated subjects (12% versus 17%, p = 0.62). Data from this phase IIa trial showed that modulation of CFTR function in patients homozygous for the F508del CFTR mutation was safe and possible, but insufficient to improve lung function over 28 days. The question remained whether administration of a combination of the corrector and the potentiator could further improve CFTR function sufficiently to improve clinical outcomes. Phase II trial Based on the results of the phase IIa trial, researchers designed a multicenter, multidose, randomized, placebo-controlled trial of ivacaftor plus lumacaftor (VX-809) in adults with CF homozygous and heterozygous for the F508del mutation [Boyle et al. 2014]. Three successive cohorts were planned, with dosing for each subsequent cohort defined by data from the previous cohort (Figure 3). The primary outcomes for the study were change in sweat chloride concentration during combination therapy, and safety. Secondary outcomes included change in lung function and change in sweat chloride from baseline in all cohorts. Change in Cystic Fibrosis Questionnaire-Revised (CFQ- R) scores was included as a secondary endpoint in cohorts 2 and 3. In cohort 1 (n = 62 subjects randomized) subjects FEV 1 did not change significantly compared with placebo in either of the lumacaftor plus ivacaftor dose groups. However, during the combination therapy treatment period, cohort 1 subjects who received 200 mg lumacaftor daily and 250 mg lumacaftor twice daily experienced a decrease in sweat chloride of 9.1 mmol/liter (95% CI 12.9 to 5.4, p < 0.001) that was significantly different from that in the placebo group ( 9.7 mmol/liter, 95% CI 14.8 to 4.6, p < 0.001). Based on these data, subjects in cohorts 2 and 3 randomized to the study drug were given a combination of lumacaftor and ivacaftor 250 mg every 12 h. Subjects in cohort 2 (n = 109 randomized) who were homozygous for the F508del CFTR mutation (n = 82) and received either 600 mg daily or 400 mg twice daily of lumacaftor plus 250 mg ivacaftor every 12 h experienced a mean increase in absolute FEV 1 % predicted (6.2, 95% CI , p < 0.001; and 6.1, 95% CI , p = , respectively) during combination treatment (but not during monotherapy). These changes in FEV 1 were significantly improved compared with placebo in these treatment groups (p < and p =0.003, respectively). Mean sweat chloride concentrations did not decrease significantly in any of the groups during the combination therapy period, although there were significant decreases over the entire study period (days 1 56) in the patients homozygous for the F508del CFTR mutation in the daily lumacaftor plus ivacaftor groups ( 9.1 mmol/liter, 95% CI 13.3 to 4.9, p < 0.001; and 8.9 mmol/liter, 95% CI 13.1 to 4.7, p < 0.001, respectively). Over the total treatment period, improvement in the respiratory portion of the CFQ-R was observed compared with the placebo group in the subjects who received lumacaftor 400 mg daily (13.5, 95% CI , p = 0.011), but not in those who received 600 mg daily. There were no statistically significant differences in sweat chloride or in lung function during combination therapy for subjects heterozygous for the F508del CFTR mutation. For subjects in cohort 3 (n = 15 patients randomized) homozygous for the F508del CFTR mutation randomized to who received twice daily lumacaftor plus twice daily ivacaftor group, mean sweat chloride concentrations did not decrease significantly during the combination therapy period, although there was a significant decrease in sweat chloride levels over the entire study period (days 1 56) ( 10.3, , p = 0.002). There was an improvement in lung function during the combination period for subjects in this cohort: a mean absolute increase in FEV 1 % predicted of 6.1 (95% CI , p = 0.004), and a mean relative increase (compared with placebo) of 7.7 (95% CI , p = 0.003). There was not a statistically significant improvement in CFQ-R respiratory scores for subjects in this cohort over the 56-day study period compared with placebo
8 Therapeutic Advances in Respiratory Disease 9(6) Figure 3. Randomization and dosing schema for cohorts 1 3 in the phase II trial of treatment of subjects homozygous for the F508del mutation with lumacaftor and ivacaftor. Adapted from Boyle et al. [2014]. Although the incidence of adverse events was similar in the combination and placebo groups, there was a dose-dependent trend towards a decline in FEV 1 % predicted in the 100 mg and 200 mg lumacaftor monotherapy treatment groups compared with placebo. Seven subjects receiving lumacaftor monotherapy discontinued treatment because of adverse events, mostly respiratory in nature (dyspnea, categorized as respiration abnormal, and chest tightness). The most common adverse events during combination therapy treatment were cough, pulmonary 320
9 K Kuk and JL Taylor-Cousar et al. exacerbation, and headache. The new onset of chest tightness and dyspnea were not more common than in placebo in subjects on combination therapy and no subjects discontinued treatment because of an adverse event during combination therapy. The rate of serious adverse events, including pulmonary exacerbation, was similar between the combination therapy and placebo groups. There were no serious adverse events corresponding to liver function test abnormalities that were caused by study drug treatment. The phase II trial revealed a number of important points for consideration in design of the phase III trials. Critically, although the improvements in CFTR function and lung function were modest compared with those observed in the studies of ivacaftor in patients with gating and conductance mutations, the phase II trial showed that modulation of F508del CFTR is possible. Second, this study provided information about dosing, specifically that the 600 mg daily or 400 mg twice daily doses of lumacaftor were most likely to be efficacious. Additionally, in spite of the drug drug interaction between lumacaftor and ivacaftor [Cholon et al. 2014; Veit et al. 2014], clinical improvements were observed during combination therapy [Boyle et al. 2014]. Although increased respiratory adverse events were observed with higher doses of lumacaftor in some subjects during monotherapy, combination therapy was overall safe and well tolerated. Finally, although the trends for patients heterozygous for the F508del mutation were similar to those homozygous for the mutation, the data demonstrated that this combination of modulator therapies was not sufficiently efficacious in heterozygotes to move forward with testing in this group. Phase III trial Using the results of the phase II trial to guide them, investigators designed two phase III clinical trials of lumacaftor ivacaftor combination therapy in patients at least 12 years of age who were homozygous for the F508del mutation [Wainwright et al. 2015]. The two studies, TRAFFIC and TRANSPORT, were run in parallel. Subjects from 187 multinational sites were randomized in a 1:1:1 fashion to one of the two most promising doses of lumacaftor, 600 mg once daily or 400 mg every 12 h, in combination with ivacaftor 250 mg every 12 h, or placebo for 24 weeks. Randomization was stratified by age, sex, and pulmonary function at screening. The primary endpoint for both studies was the absolute change from baseline in the FEV 1 % predicted at 24 weeks. Secondary endpoints for both studies included the relative change from baseline in the FEV 1 % predicted, absolute change from baseline at week 24 in BMI and CFQ-R respiratory domain, percentage of patients with a relative increase of at least 5% in FEV 1 % predicted, and number of pulmonary exacerbations over the 24 weeks of the study. Of the 1122 patients who were randomized, 1108 received at least one dose of study drug. The mean age of the subjects across the dosing groups was approximately 25 years of age. Approximately half of the subjects were women, and their baseline FEV 1 % predicted was around 61%. Consistent with this degree of lung dysfunction, the majority of patients were concomitantly treated with bronchodilators, dornase alfa, inhaled antibiotics, azithromycin inhaled hypertonic saline, and inhaled glucocorticoids. In this heavily treated patient population, combination therapy led to modest improvements in the primary and secondary endpoints of the study. Compared with placebo, the mean absolute change in FEV 1 % predicted from baseline to week 24 was significantly improved in all dose groups in the individual studies (TRAFFIC: 2.6 4%, TRANSPORT: 2.6 3%, p < 0.001), and in the pooled data ( %, p < 0.001). The relative change in FEV 1 % predicted from baseline to 24 weeks was also significantly improved in all dose groups in both studies (TRAFFIC: %, TRANSPORT: %, p < 0.001) and in the pooled data ( %, p < 0.001). These changes in FEV 1 occurred within 15 days of the start of the study drug and were sustained through the 24 weeks of the trial. Furthermore, the improvement in FEV 1 % predicted was consistent across all subgroups tested, including age (children versus adults 18 years), severity of lung disease (mild, moderate, or severe), and sex and Pseudomonas aeruginosa infection status. Finally, based on the pooled data, the odds ratio for a relative increase of at least 5% from baseline in FEV 1 % predicted was 2.2 (95% CI , p < 0.001) for the subjects receiving 400 mg twice daily plus ivacaftor, and 3.1 (95% CI , p < 0.001) compared with placebo. In addition to modest improvements in lung function, there were also improvements in important secondary endpoints. Most remarkably, 321
10 Therapeutic Advances in Respiratory Disease 9(6) compared with placebo, there was a 30% lower rate of protocol-defined pulmonary exacerbations in the 600 mg lumacaftor group (p = 0.001) and a 39% lower exacerbation rate in the 400 mg twice daily lumacaftor ivacaftor group (p < 0.001). Notably, compared with placebo, there was a higher proportion of subjects who were exacerbation free at the end of the 24-week trial in the pooled lumacaftor ivacaftor dosing groups. Pulmonary exacerbations leading to intravenous antibiotics or hospitalization were also reduced in the lumacaftor ivacaftor treated groups compared with placebo [lumacaftor 600 mg daily plus ivacaftor: 45% reduction in events leading to intravenous antibiotic therapy (p < 0.001) and 39% reduction in events leading to hospitalization (p = 0.003); lumacaftor 400 mg every 12 h plus ivacaftor: 56% reduction in events leading to intravenous antibiotic therapy (p < 0.001) and 61% reduction in events leading to intravenous antibiotic therapy (p < 0.001)]. Also based on pooled data from the two studies, there were statistically significant improvements in absolute change from baseline in BMI in both dosing groups ( , p < 0.001). Finally, although there was a statistically significant point improvement in the respiratory portion of the CFQ-R (p = 0.05 and for the lumacaftor 400 mg ivacaftor group and 600 mg ivacaftor group, respectively), this improvement does not meet the previously defined minimally important clinical difference for this outcome [Quittner et al. 2009]. Safety and tolerability results were consistent with those seen in the phase II studies. In general, similar rates of adverse events (most commonly pulmonary exacerbations, cough, and headache) were observed in the placebo and lumacaftor ivacaftor groups. However, dyspnea and chest tightness were more often seen in those treated with lumacaftor ivacaftor ( % and %, respectively) than in placebo-treated subjects (7.8% and 5.9%, respectively). Furthermore, the proportion of subjects who discontinued treatment was higher in those receiving lumacaftor ivacaftor. It is noteworthy that for those subjects that chose to continue in the study in spite of the early emergence of respiratory-related adverse events, the respiratory symptoms generally resolved within 2 3 weeks of continued treatment. The most common serious adverse event in all treatment groups was pulmonary exacerbation, which occurred more frequently in the placebo group (24.1% of the patients versus 13.0% in the pooled lumacaftor ivacaftor group). Rates of clinically significant elevations of liver function tests were similar in the placebo and lumacaftor ivacaftor treated subjects (5.1% versus 5.2%). However, while there were no liver-related serious adverse events in the placebo group, seven events occurred in the subjects receiving combination therapy. Liver function returned to baseline in six of seven patients following discontinuation or interruption of lumacaftor ivacaftor therapy. In summary, based on the data from two phase III studies, lumacaftor ivacaftor combination therapy was safe and relatively well tolerated with the exception of a small percentage of patients who experienced increased dyspnea and chest tightness. Combination therapy modestly improved lung function and led to clinically important decreased rates of pulmonary exacerbations in subjects homozygous for the F508del mutation. Outcome data were similar for the two lumacaftor ivacaftor dosing groups with the exception that the effect on exacerbations was stronger for the lumacaftor 400 mg plus ivacaftor group. Based on these data, in November 2014, Vertex Pharmaceuticals submitted a New Drug Application (NDA) for approval of the combination of lumacaftor ivacaftor (lumacaftor 400 mg and ivacaftor 250 mg every 12 h) in patients with CF who are at least 12 years of age and are homozygous for the F508del mutation. Future directions On 12 May 2015, the PADAC to the FDA held a meeting to review safety, efficacy, and the potentially appropriate use of lumacaftor ivacaftor therapy. Physicians with expertise in CF and patients who had participated in the clinical trials spoke at the hearing. The PADAC voted 12 1 to approve the lumacaftor ivacaftor combination (proposed trade name, Orkambi) for use in people with CF who are at least 12 years of age and are homozygous for the F508del mutation. Under the Prescription Drug User Fee Act, the FDA approved the Orkambi (Vertex Pharmaceuticals Boston, MA) NDA on 2 July [FDA, 2015]. Although only very limited data from trials of ivacaftor in patients with FEV 1 less than 40% were available at the time of its FDA review, ivacaftor was approved for patients with the G551D 322
11 K Kuk and JL Taylor-Cousar et al. mutation without a lung function restriction [Vertex Pharmaceuticals, 2015]. As in the case with ivacaftor, and most studies of new therapeutic agents in patients with CF, patients with severe disease were excluded from the phase III studies of lumacaftor ivacaftor [Wainwright et al. 2015]. Because treatment options for this group of patients are limited, patients with severe CF who are homozygous for the F508del mutation will be very interested in trying this new therapy. Particularly in light of the increased incidence of chest tightness in patients in the treated versus placebo group [Wainwright et al. 2015], safety and tolerance data in the group of patients with severe CF lung disease are crucial. A 6-month open-label study of lumacaftor ivacaftor therapy in subjects homozygous for the F508del mutation who are over 12 years with FEV 1 less than 40% or actively listed for lung transplant is currently enrolling [ClinicalTrials.gov identifier: NCT ]. Lack of validated surrogate endpoints in children under the age of 6 years makes it difficult to prove efficacy in this group. However, safety was shown in a clinical trial of ivacaftor in children aged 2 5 years old with gating mutations [ClinicalTrials. gov identifier: NCT ]. This trial led to approval of ivacaftor for patients at least 2 years old with CF with gating mutations [Vertex Pharmaceuticals, 2015]. Because it is clear that lung disease is present from a very young age [Stick et al. 2009], it will be important to conduct safety and efficacy studies in 6 11-year-old patients and safety studies in patients under the age of 5 years. With its approval, lumacaftor ivacaftor combination therapy is the first modulator therapy approved that will potentially treat almost half of the patients with CF. Though the effects on important clinical endpoints including lung function and BMI were small [Wainwright et al. 2015], it is a first step. Given the complex pathophysiology of F508del CFTR mutation dysfunction, two or more small molecules may be required to adequately correct and potentiate the resultant malfunctioning protein. Investigation of other novel small molecule modulator therapies is underway. For example, the oral potentiator, QBW251, is being evaluated in a phase II trial in adult patients with CF who are heterozygous for mutations resulting in dysfunctional CFTR channels present at the cell surface [ClinicalTrials.gov identifier: NCT ]. Additionally, a phase Ib trial has recently been completed using N91115, an oral S-nitrosoglutathione reductase inhibitor shown in vitro to stabilize F508del CFTR [ClinicalTrials. gov identifier: NCT ]. Finally, VX-661, an oral CFTR corrector, is being studied in combination with ivacaftor in phase III subjects homozygous [ClinicalTrials.gov identifier: NCT ] and heterozygous for the F508del mutation [ClinicalTrials.gov identifier: NCT , NCT ]. In addition to evaluation of novel small molecules for CFTR correction, drugs approved for other disease states with potential CFTR activity are being studied. Early phase clinical trials of riociguat (approved for treatment of pulmonary hypertension) and miglustat (approved for type I Gaucher s and Niemann Pick disease) are actively recruiting patients with CF homozygous for the F508del CFTR mutation[clinicaltrials. gov identifier: NCT , NCT ]. While the majority of patients may be treated with modulators that effect mutations defective in their folding, gating and conductance, approximately 10% [Peltz et al. 2013] of patients have mutations ( nonsense mutations ) that result in prematurely truncated CFTR protein. A clinical trial of a therapeutic agent that promotes read-through of premature truncation codons is also enrolling [ClinicalTrials.gov identifier: NCT ]. For the remaining 2% of mutations that are unlikely to respond to modulator therapy with small molecules, DNA or RNA editing through oligonucleotide therapy may be an option in the future [McNeer et al. 2015]. Prior to the approval of ivacaftor for patients with the G551D mutation, Mackenzie and colleagues projected that if mortality in CF continued to decrease at the rate observed between 2000 and 2010, predicted median survival for a child born in 2010 would be over 50 years [Mackenzie et al. 2014]. This predicted age is still well below the current survival of the non-cf US population. However, based on the effect of CFTR modulators on FEV 1 (our best predictor of mortality in CF) [Kerem et al. 1992], we may rapidly close this survival gap. Acknowledgements The first draft of the pharmacokinetics section was written by KK. The remainder of the first draft was written by JTC. JTC revised the final 323
12 Therapeutic Advances in Respiratory Disease 9(6) document. Both authors approved the final version of the manuscript. This manuscript has not been submitted or published elsewhere. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. Declaration of Conflicting Interests The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JTC has served as an investigator with grant funding paid to her institution for Vertex Pharmaceuticals Inc., N30 Pharmaceuticals Inc., and Gilead Pharmaceuticals Inc., and has participated in advisory boards for Vertex Pharmaceuticals Inc., Novartis Pharmaceuticals Inc. and Gilead Pharmaceuticals Inc. She has received grant funding paid to her institution from the Cystic Fibrosis Foundation and the National Institutes of Health. KK has no conflicts of interest to declare. References Accurso, F., Rowe, S., Clancy, J., Boyle, M., Dunitz, J., Durie, P. et al. (2010) Effect of Vx-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: Andersen, D. (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56: Barry, P., Plant, B., Nair, A., Bicknell, S., Simmonds, N., Bell, N. et al. (2014) Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest 146: Borowitz, D. and Gelfond, D. (2013) Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 19: Boyle, M., Bell, S., Konstan, M., McColley, S., Rowe, S., Rietschel, E. et al. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2: Boyle, M. and De Boeck, K. (2013) A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 1: CFF (2013) Cystic Fibrosis Foundation National Patient Registry Annual Data Report. Bethesda, MD. CFF (2015) Cystic Fibrosis Foundation. Retrieved from: Cholon, D., Quinney, N., Fulcher, M., Esther, C., Jr, Das, J., Dokholyan, N. et al. (2014) Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 6: 246ra296. Clancy, J., Rowe, S., Accurso, F., Aitken, M., Amin, R., Ashlock, M. et al. (2012) Results of a phase IIa study of VX-809, an investigational CFTR Corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: Davies, J., Wainwright, C., Canny, G., Chilvers, M., Howenstine, M., Munck, A. et al. (2013) Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187: De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G. et al. (2014) Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-g551d gating mutation. J Cyst Fibros 13: Denning, G., Ostedgaard, L. and Welsh, M. (1992) Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 118: Donaldson, S., Bennett, W., Zeman, K., Knowles, M., Tarran, R. and Boucher, R. (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: Elkins, M., Robinson, M., Rose, B., Harbour, C., Moriarty, C., Marks, G. et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: FDA (2015) U. S. Food and Drug Administration Advisory Committee Report. Silver Spring, MD. Flume, P., Liou, T., Borowitz, D., Li, H., Yen, K., Ordonez, C. et al. (2012) Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del- CFTR mutation. Chest 142: Fuchs, H., Borowitz, D., Christiansen, D., Morris, E., Nash, M., Ramsey, B. et al. (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331: Gibson, R., Burns, J. and Ramsey, B. (2003) Pathophysiology and management of pulmonary 324
13 K Kuk and JL Taylor-Cousar et al. infections in cystic fibrosis. Am J Respir Crit Care Med 168: Griesenbach, U. and Alton, E. (2013) Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 22: R52 R58. Hebestreit, H., Sauer-Heilborn, A., Fischer, R., Kading, M. and Mainz, J. (2013) Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551d mutation. J Cyst Fibros 12: Ikuma, M. and Welsh, M. (2000) Regulation of CFTR Cl- channel gating by ATP binding and hydrolysis. Proc Natl Acad Sci U S A 97: Kerem, B., Rommens, J., Buchanan, J., Markiewicz, D., Cox, T., Chakravarti, A. et al. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: Kerem, E., Reisman, J., Corey, M., Canny, G. and Levison, H. (1992) Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326: Konstan, M., Byard, P., Hoppel, C. and Davis, P. (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332: Konstan, M., Vandevanter, D., Rasouliyan, L., Pasta, D., Yegin, A., Morgan, W. et al. (2010) Trends in the use of routine therapies in cystic fibrosis: Pediatr Pulmonol 45: Mackenzie, T., Gifford, A., Sabadosa, K., Quinton, H., Knapp, E., Goss, C. et al. (2014) Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med 161: McKone, E., Borowitz, D., Drevinek, P., Griese, M., Konstan, M., Wainwright, C. et al. (2014) Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2: McNeer, N., Anandalingam, K., Fields, R., Caputo, C., Kopic, S., Gupta, A. et al. (2015) Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nat Commun 6: Oermann, C., Retsch-Bogart, G., Quittner, A., Gibson, R., McCoy, K., Montgomery, A. et al. (2010) An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 45: Peltz, S., Morsy, M., Welch, E. and Jacobson, A. (2013) Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64: Quittner, A., Modi, A., Wainwright, C., Otto, K., Kirihara, J. and Montgomery, A. (2009) Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135: Ramsey, B., Davies, J., McElvaney, N., Tullis, E., Bell, S., Drevinek, P. et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: Ramsey, B., Pepe, M., Quan, J., Otto, K., Montgomery, A., Williams-Warren, J. et al. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340: Riordan, J., Rommens, J., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z. et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: Rommens, J., Iannuzzi, M., Kerem, B., Drumm, M., Melmer, G., Dean, M. et al. (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245: Rowe, S., Heltshe, S., Gonska, T., Donaldson, S., Borowitz, D., Gelfond, D. et al. (2014) Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190: Rowe, S., Miller, S. and Sorscher, E. (2005) Cystic fibrosis. N Engl J Med 352: Saiman, L., Anstead, M., Mayer-Hamblett, N., Lands, L., Kloster, M., Hocevar-Trnka, J. et al. (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303: Saiman, L., Marshall, B., Mayer-Hamblett, N., Burns, J., Quittner, A., Cibene, D. et al. (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: Stick, S., Brennan, S., Murray, C., Douglas, T., Von Ungern-Sternberg, B., Garratt, L. et al. (2009) Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 155: e621. Taylor-Cousar, J., Niknian, M., Gilmartin, G., Pilewski, J. for the VX Investigators (2015) Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the 325
Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs
Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41
More informationCystic Fibrosis Foundation Patient Registry 2013
5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical
More informationCystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Cystic Fibrosis Agents (Kalydeco, Orkambi ) Rx.01.117 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationThe Future of CF Therapy
The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationDisclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016
Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy Susanna A McColley, MD Associate Chief Research Officer Stanley Manne Children s Research Institute
More information"Management and Treatment of Patients with Cystic fibrosis (CF)
"Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March
More informationPA Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationRespiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationCystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
More informationPediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.
Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationEnabling CF Therapeutic Development
Enabling CF Therapeutic Development PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs No Disclosures Cystic Fibrosis In 1955 In 1955 most children with CF did not live long enough
More informationA Genetic Approach to the Treatment of Cystic Fibrosis
A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March
More informationYou Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM
You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative
More informationTargeted therapies to improve CFTR function in cystic fibrosis
Brodlie et al. Genome Medicine (2015) 7:101 DOI 10.1186/s13073-015-0223-6 REVIEW Targeted therapies to improve CFTR function in cystic fibrosis Malcolm Brodlie 1*, Iram J. Haq 2, Katie Roberts 2 and J.
More informationBriefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee
FDA Advisory Committee Briefing Materials Page 1 of 157 Briefing Document FDA Pulmonary - Allergy Drugs Advisory Committee Ivacaftor for the Treatment of Cystic Fibrosis in Patients Age 6 Years and Older
More informationCystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus
Eur Respir Rev 2013; 22: 127, 66 71 DOI: 10.1183/09059180.00008512 CopyrightßERS 2013 REVIEW Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Isabelle Sermet-Gaudelus ABSTRACT:
More informationA CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation A BS TR AC T
The new england journal of medicine established in 112 november 3, 2011 vol. 365 no. 1 A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation Bonnie W. Ramsey, M.D., Jane Davies, M.D.,
More informationClass Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClass Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCF: Understanding the Biology Curing the Disease
CF: Understanding the Biology Curing the Disease Scott H. Donaldson, MD Associate Professor of Medicine Director, Adult CF Care Center University of North Carolina at Chapel Hill Defining the path Drilling
More informationClinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations) Reference: NHS England: A01/P/c NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and
More informationChronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients
Journal of Cystic Fibrosis 12 (2013) 482 486 www.elsevier.com/locate/jcf Original Article Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients
More informationWhat is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
More informationDrug Use Criteria: Ivacaftor (Kalydeco ) and Lumacaftor/Ivacaftor (Orkambi )
Texas Vendor Program Use Criteria: (Kalydeco ) and Lumacaftor/ (Orkambi ) Publication History Developed: October 2012 Revised: December 2017; February 2016; June 2014. Notes: Information on indications
More informationKalydeco. Kalydeco (ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco
More informationOral Cystic Fibrosis Modulators
Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 November 2014 KALYDECO 150 mg, film-coated tablet B/56 (CIP: 34009 266 060 5 3) Applicant: VERTEX INN ATC code Reason
More informationBrand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated
Brand Name: Kalydeco Generic: ivacaftor Manufacturer 1 : Vertex Pharmaceuticals Incorporated Drug Class 2,3 : Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator Uses: Labeled Uses 1,2,3,4,5
More informationPharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there
More informationCharacterizing aggressiveness and predicting future progression of CF lung disease
Journal of Cystic Fibrosis Volume 8 Suppl 1 (2009) S15 S19 www.elsevier.com/locate/jcf Characterizing aggressiveness and predicting future progression of CF lung disease Michael W. Konstan a, *, Jeffrey
More informationRecently, the cystic fibrosis (CF) community celebrated the 25th
focused review A new era of personalized medicine for cystic fibrosis at last! Bradley S Quon MD MSc FRCPC 1,2, Pearce G Wilcox MD FRCPC 1,2 BS Quon, PG Wilcox. A new era of personalized medicine for cystic
More informationA Quick Guide to the. I507del. Mutation CFTR SCIENCE
A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum
More informationCystic fibrosis: hitting the target
Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas
More informationNew Drug Evaluation: Lumacaftor/Ivacaftor
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGoals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy
CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive
More informationCYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
More informationScottish Paediatric Cystic Fibrosis MCN. Protocols / Guidelines. Ivacaftor: A guideline for use in paediatric CF patients in Scotland
Scottish Paediatric Cystic Fibrosis MCN Protocols / Guidelines Ivacaftor: A guideline for use in paediatric CF patients in Scotland Authors: Dr Carol Dryden Dr Jane Wilkinson Miss Julie Crocker, Registered
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex
More informationLumacaftor Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
The new england journal of medicine Original Article Lumacaftor Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR C.E. Wainwright, J.S. Elborn, B.W. Ramsey, G. Marigowda, X. Huang,
More informationNorth American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationOutcome measures for clinical trials assessing treatment of cystic fibrosis lung disease
Review: Clinical Trial Methodology Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease Clin. Invest. (2012) 2(2), 163 175 Cystic fibrosis (CF) is a complex genetic
More informationOpinion 7 November 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 7 November 2012 KALYDECO 150 mg film-coated tablets B/56 (CIP code: 34009 266 060 5 3) Applicant: VERTEX INN ATC Code
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, 2012 ClinicalTrials.gov ID: NCT00457821 Study Identification Unique Protocol ID: VX06-770-101 Brief Title:
More informationSymdeko. Symdeko (tezacaftor and ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.10 Subject: Symdeko Page: 1 of 5 Last Review Date: June 22, 2018 Symdeko Description Symdeko (tezacaftor
More informationClinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages)
Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages) NHS England Reference: 1732P NHS England INFORMATION READER BOX Directorate
More informationOpening Doors to CF Clinical Research: Change is Coming
Opening Doors to CF Clinical Research: Change is Coming Disclosures Contracts with sponsors for clinical trials conducted at UNC-Chapel Hill: CFFT NIH/NHLBI AbbVie Inc. Aptalis Pharma US, Inc. Janssen
More informationNew and investigational treatments in cystic fibrosis
Therapeutic Advances in Respiratory Disease Review New and investigational treatments in cystic fibrosis Mangala Narasimhan and Rubin Cohen Ther Adv Respir Dis (2011) 5(4) 275 282 DOI: 10.1177/ 1753465811398267!
More informationExploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis
CME/CNE/CPE Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis Course Director Jerry Nick, MD National Jewish Health University of Colorado Denver,
More informationWe strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis
Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward
More information(<40 and 40) and screening ppfev 1. , were done for patients with baseline ppfev 1
Efficacy and safety of lumacaftor/ivacaftor combinion therapy in pients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis J Stuart Elborn, Bonnie W Ramsey,
More informationCystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
More informationCost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation
Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation January 2013 1. A rapid review submission on the drug ivacaftor
More informationCavosonstat Phase 2 Trial Results. November 28 th, 2016
Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David
More informationOrkambi. Orkambi (lumacaftor/ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.06 Subject: Orkambi Page: 1 of 6 Last Review Date: November 30, 2018 Orkambi Description Orkambi (lumacaftor/ivacaftor)
More informationKey Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal
1 2 3 Cystic fibrosis is a rare life-long genetic disease that affects approximately 4,000 people in Canada and about 70,000 worldwide regardless of race or ethnicity but is more common in Caucasians 1,2
More informationNorth American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationInvited Article. A Historical Perspective of Cystic Fibrosis RW WILMOTT. Key words. Introduction. Cystic Fibrosis in History
HK J Paediatr (new series) 2016;21:280-285 Invited Article A Historical Perspective of Cystic Fibrosis RW WILMOTT Abstract Key words Cystic fibrosis (CF) is an autosomal recessive genetic disease caused
More informationErratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample
Qual Life Res (2012) 21:1279 1290 DOI 10.1007/s11136-011-0091-5 ERRATUM Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample Alexandra L. Quittner Gregory
More informationPhase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures
Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael
More informationivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd
ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd 04 November 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationThe management of cystic fibrosis (CF) has improved. clinical investigations. Factors Influencing Outcomes in Cystic Fibrosis* A Center-Based Analysis
clinical investigations Factors Influencing Outcomes in Cystic Fibrosis* A Center-Based Analysis Charles Johnson, MB, ChB; Steven M. Butler, PhD; Michael W. Konstan, MD; Wayne Morgan, MD; and Mary Ellen
More informationGLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1)
GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1) ECFS, Sevilla, Spain 9 June 2017 Jane Davies on behalf of the SAPHIRA1 Study Team Copyright
More informationCase Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?
Names: Date: Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis? Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the
More informationCFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis*
Original Research CYSTIC FIBROSIS CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis* Edward F. McKone, MD, MS; Christopher H. Goss, MD, MS, FCCP; and Moira L. Aitken, MD, FCCP Study rationale:
More informationAzithromycin may antagonize inhaled tobramycin when targeting P. aeruginosa in cystic fibrosis
Data Supplement Azithromycin may antagonize inhaled tobramycin when targeting P. aeruginosa in cystic fibrosis Jerry A. Nick 1, Samuel M. Moskowitz 2, James F. Chmiel 3, Anna V. Forssén 4, Sun Ho Kim 2,
More informationCystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS
Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =
More informationTreatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes
Journal of Cystic Fibrosis 12 (2013) 461 467 www.elsevier.com/locate/jcf Original Article Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes Gregory
More informationA Case of Cystic Fibrosis
Name(s) Date A Case of Cystic Fibrosis Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the day. The baby's parents had brought young Zoey to the emergency
More informationCystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.
1938 OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children. : The beginning May 1938: 49 cases 25 20 15 Nos of cases 10 5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Age
More informationClinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)
Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults) Reference: NHS England 1621 First published: Month Year Prepared
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION LUMACAFTOR / IVACAFTOR (Orkambi Vertex Pharmaceuticals [Canada] Inc.) Indication: Cystic Fibrosis, F508del-CFTR mutation Recommendation: The CADTH
More informationCystic fibrosis: From the gene to the disease
Cystic fibrosis: From the gene to the disease Christiane Knoop, MD, PhD Institut de Mucoviscidose de l ULB Hôpital Erasme christiane.knoop@erasme.ulb.ac.be Cystic fibrosis «The infant that tastes of salt
More informationCYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE
CYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE I - INTRODUCTION a) Cystic Fibrosis Cystic fibrosis (CF) is the most common fatal genetic
More informationA treatment option for patients with CF who have responsive mutations
A treatment option for patients with CF who have responsive mutations INDICATIONS AND USAGE SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are
More informationCystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL
Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Objectives: At the end of the presentation the listeners will Be able to describe neonatal
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationClinical Commissioning Policy: Continuous aztreonam lysine for cystic fibrosis (all ages)
Clinical Commissioning Policy: Continuous aztreonam lysine for cystic fibrosis (all ages) Reference: NHS England: 16001/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationPulmonary Perspective
Pulmonary Perspective Personalized Medicine in Cystic Fibrosis Dawning of a New Era John P. Clancy 1 * and Manu Jain 2 * 1 Cincinnati Children s Hospital Medical Center and the University of Cincinnati,
More informationEffect of pulmonary exacerbations on long-term lung function. decline in cystic fibrosis
ERJ Express. Published on December 1, 2011 as doi: 10.1183/09031936.00159111 Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Valerie Waters 1*, MD, MSc, Sanja Stanojevic
More informationCYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION
CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION A Program for the CF Center Care Team Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex
More informationCystic Fibrosis Update
Cystic Fibrosis Update More than Decades of Discovery Dr. Raj Padman Professor of Pediatric TJU Board certified in Pediatrics, Pulmonology, and Sleep Medicine Dupont, Kosciusko Community, Lutheran, Rehabilitation,
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex
More informationPediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives
Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other
More informationCYSTIC FIBROSIS (CF) COMPLICATIONS BEYOND THE LUNGS. A Resource for the CF Center Care Team
CYSTIC FIBROSIS (CF) COMPLICATIONS BEYOND THE LUNGS A Resource for the CF Center Care Team Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo
More informationNACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV
NACFC investor meeting Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC 2017 2 November 2017 Copyright 2017 Galapagos NV Disclaimer This presentation contains forward-looking statements,
More informationCystic Fibrosis Diagnosis and Treatment
Cystic Fibrosis Diagnosis and Treatment Financial Disclosures Personal financial relationships with commercial interests relevant to medicine, within the past 3 years: NJH site PI for AstraZeneca. As faculty
More informationRESEARCH. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007
Improved survival at low lung function in cystic fibrosis: cohort study from 199 to 27 P M George, academic registrar in respiratory medicine, 1 W Banya, medical statistician, 2 N Pareek, specialist trainee
More informationBruce C Marshall, 1 Eugene C Nelson 2 SUPPLEMENT. i95
SUPPLEMENT Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative Bruce C Marshall,
More informationPhase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients
Phase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients July 18, 2017 Agenda Introduction Michael Partridge, VP Investor Relations
More informationRecent advances in the management of cystic fibrosis
REPORT Recent advances in the management of cystic fibrosis DANNY BUCKLAND More effective management programmes and treatments mean that life expectancy for people with cystic fibrosis is improving. This
More informationMacrolide therapy in cystic fibrosis: new developments in clinical use
Macrolide therapy in cystic fibrosis: new developments in clinical use Clin. Invest. (2013) 3(12), 1179 1186 Macrolide therapy, in particular azithromycin, has been shown to improve aspects of lung health
More informationPulmonary Exacerbations:
Pulmonary Exacerbations: Better Understanding Needed Michael Tracy, MD Clinical Assistant Professor Pediatric Pulmonary CF Pulmonary Exacerbations Definition Importance Causes Treatment Research opportunities
More information